| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Lyme Disease Antibody with Reflex to Blot (IgG, IgM) : 6646
Test CodeLYMABQ : 6646
Alias/See Also
Borrelia burgdorferi
CPT Codes
86618
Includes
If Lyme Disease Antibody Screen is ≥0.90, then Lyme Disease Antibodies (IgG, IgM), Immunoblot will be performed at an additional charge (CPT code(s): 86617 x2 code LYMWBQ IC 8593 ).
Transport Container
Specimen:
1 mL serum
Minimum Volume 0.7 mL
1 mL serum
Minimum Volume 0.7 mL
Transport Temperature
Room temperature.
Specimen Stability
Room Temperature: 7 days; Refrigerated: 14 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, Grossly lipemic, Grossly icteric
Methodology
Immunoassay
Setup Schedule
Sunday, Tuesday - Saturday
Report Available
1-3 days (From receipt at performing laboratory)
Reference Range
Index Interpretation
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
As recommended by the Food and Drug Administration (FDA), all samples with positive or equivocal results in a Borrelia burgdorferi antibody screen will be tested using a blot method. Positive or equivocal screening test results should not be interpreted as truly positive until verified as such using a supplemental assay (e.g., B. burgdorferi blot).
The screening test and/or blot for B. burgdorferi antibodies may be falsely negative in early stages of Lyme disease, including the period when erythema migrans is apparent.
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
As recommended by the Food and Drug Administration (FDA), all samples with positive or equivocal results in a Borrelia burgdorferi antibody screen will be tested using a blot method. Positive or equivocal screening test results should not be interpreted as truly positive until verified as such using a supplemental assay (e.g., B. burgdorferi blot).
The screening test and/or blot for B. burgdorferi antibodies may be falsely negative in early stages of Lyme disease, including the period when erythema migrans is apparent.
Clinical Significance
Lyme disease is caused by a bacterium borrelia burgdorferi and is transmitted by ticks. A screening test with high sensitivity is used as the first step in the CDC recommended algorithm. Immunoblot testing qualitatively examines, with high specificity, antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected screening result.
Performing Laboratory
Quest Diagnostics
